WADAs Summary of Major Modifications and Explanatory Notes is available and weve explained the major changes, as well as some of the minor clarifications, below
Tirzepatide in particular has been found to have dramatic benefits for weight loss, with weekly injections in patients with obesity and without diabetes leading to an average reduction of 20.9% in weight at the maximum evaluated dose of 15 mg, compared to an average of 3.1% in the placebo arm [16]
GLP-1 receptor agonists function by: Stimulating insulin release when blood sugar levels are high Reducing glucagon secretion, which helps lower blood sugar Slowing gastric emptying, leading to increased satiety Affecting appetite centers in the brain, reducing food intake While these mechanisms contribute to the drugs effectiveness, they may also play a role in potential side effects, including the rare but serious risk of NAION
doi: 10.1210/10.1210/er.2006-0038 8 Dallinga-ThieGMNieuwdorpM
It does not provide preparation, reconstitution, dosing, injection, administration, cycling, stacking, purchasing or self-experimentation guidance